(R)-SL18

(R)-SL18 binds to purified ANXA3 protein with a K_d of 1.15 μM^[1].
(R)-SL18 inhibits proliferation of MDA-MB-468 TNBC cells with an IC₅₀ of 2.45 μM^[1].
(R)-SL18 inhibits proliferation of MDA-MB-231 TNBC cells with an IC₅₀ of 3.53 μM^[1].
(R)-SL18 (0.25-1.0 μM μM; 24 h) reduces migration of MDA-MB-468 TNBC cells by 52-62%^[1].
(R)-SL18 (0.625-2.5 μM; 24 h) reduces migration of MDA-MB-231 TNBC cells by 46-51% at 0.625 μM, 82-87% at 1.25 μM, and 93-95% at 2.5 μM after 24 h of treatment^[1].
(R)-SL18 (0.25-1.0 μM) reduces invasion of MDA-MB-468 TNBC cells by 13-19% at low concentration, 24-35% at medium concentration, and 47-61% at high concentration^[1].
(R)-SL18 (0.625-2.5 μM) reduces invasion of MDA-MB-231 TNBC cells by 23-31% at low concentration, 31-42% at medium concentration, and 71-76% at high concentration^[1].
(R)-SL18 (0.25-1.0 μM; 14-21 days) reduces colony formation of MDA-MB-468 TNBC cells by 12-24% at low concentration, 26-35% at medium concentration, and 49-52% at high concentration over 14-21 days with redosing every 3 days^[1].
(R)-SL18 (0.625-2.5 μM; 14-21 days) reduces colony formation of MDA-MB-231 TNBC cells by 2-23% at low concentration, 33-38% at medium concentration, and 60-68% at high concentration over 14-21 days with redosing every 3 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.